共 50 条
- [31] A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumabDIABETOLOGIA, 2024, 67 (01) : 27 - 41Mathieu, ChantalWiedeman, AliceCerosaletti, KarenLong, S. AliceSerti, ElisavetCooney, LauraVermeiren, JoanCaluwaerts, SilviaVan Huynegem, KarolienSteidler, LotharBlomme, SvenRottiers, PieterNepom, Gerald T.Herold, Kevan C.
- [32] First-in-human use of a modular capsid virus-like vaccine platform: an open-label, non-randomised, phase 1 clinical trial of the SARS-CoV-2 vaccine ABNCoV2LANCET MICROBE, 2023, 4 (03): : E140 - E148Smit, Merel J.Sander, Adam F.Ariaans, Maud B. P. A.Fougeroux, CyrielleHeinzel, ConstanzeFendel, RolfEsen, MeralKremsner, Peter G.ter Heine, RobWertheim, Heiman F.Idorn, ManjaUnderwood, Alexander P.Binderup, AlekxanderRamirez, SantseharayBukh, JensSoegaard, MaxErdogan, Sayit M.Gustavsson, TobiasClemmensen, StineTheander, Thor G.Microbe, LancetSalanti, AliHamborg, Mettede Jongh, Willem A.McCall, Matthew B. B.Nielsen, Morten A.Mordmuller, Benjamin G.
- [33] Velaglucerase alfa enzyme replacement therapy in children and adolescents with type 3 Gaucher disease: Results of a 12-month multicenter, open-label phase 1/2 studyMOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S111 - S111Tantawy, Azza A. G.El-Beshlawy, AmalMarzouk, ImanBavdekar, AshishQin, YulinMellgard, BjoernBen Turkia, Hadhami
- [34] Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trialLANCET MICROBE, 2022, 3 (09): : E663 - E671Jenkin, DanielRitchie, Adam J.Aboagye, JeremyFedosyuk, SofiyaThorley, LukeProvstgaad-Morys, SamuelSanders, HelenBellamy, DuncanMakinson, RebeccaXiang, Zhi QuanBolam, EmmaTarrant, RichardLopez, Fernando RamosPlatt, AbigailPoulton, IanGreen, CatherineErtl, Hildegund C. J.Ewer, Katie J.Douglas, Alexander D.
- [35] Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trialLANCET, 2016, 388 (10043): : 476 - 487Sessa, MarioLorioli, LauraFumagalli, FrancescaAcquati, SerenaRedaelli, DanielaBaldoli, CristinaCanale, SabrinaLopez, Ignazio D.Morena, FrancescoCalabria, AndreaFiori, RossanoSilvani, PaoloRancoita, Paolo M. V.Gabaldo, MichelaBenedicenti, FabrizioAntonioli, GigliolaAssanelli, AndreaCicalese, Maria Piadel Carro, UbaldoSora, Maria Grazia NataliMartino, SabatoQuattrini, AngeloMontini, EugenioDi Serio, CieliaCiceri, FabioRoncarolo, Maria GraziaAiuti, AlessandroNaldini, LuigiBiffi, Alessandra
- [36] Safety and immunogenicity of an HIV-1 prefusion- stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label , randomized, dose-escalation, phase 1 clinical trialECLINICALMEDICINE, 2022, 48Houser, Katherine, VGaudinski, Martin R.Happe, MyraNarpala, SandeepVerardi, RaffaelloSarfo, Edward K.Corrigan, Angela R.Wu, RichardRothwell, Ro ShaunaNovik, LauraHendel, Cynthia S.Gordon, Ingelise J.Berkowitz, Nina M.Cartagena, Cora TrellesWidge, Alicia T.Coates, Emily E.Strom, LarisaHickman, SomiaConan-Cibotti, MichelleVazquez, SandraTrofymenko, OlgaPlummer, SarahStein, JudyCase, Christopher L.Nason, MarthaBiju, AndreaParchment, Danealle K.Changela, AnitaCheng, ChengDuan, HongyingGeng, HuiTeng, I-TingZhou, TongqingO'Connell, SarahBarry, ChrisCarlton, KevinGall, Jason G.Flach, BrittaDoria-Rose, Nicole A.Graham, Barney S.Koup, Richard A.McDermott, Adrian B.Mascola, John R.Kwong, Peter D.Ledgerwood, Julie E.
- [37] A first-in-human, phase 1, open-label trial of FX201, an intra-articular, helper-dependent adenoviral gene therapy for osteoarthritis - preliminary evaluation of clinical activity in 8 patients from the mid-dose cohort of a single ascending dose study designHUMAN GENE THERAPY, 2021, 32 (19-20) : A73 - A73Kivitz, A.Senter, B.Golod, D.Parenti, D.Cinar, A.Hong, W.
- [38] Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studyLANCET ONCOLOGY, 2018, 19 (05): : 649 - 659Italiano, AntoineSoria, Jean-CharlesToulmonde, MaudMichot, Jean-MarieLucchesi, CarloVarga, AndreaCoindre, Jean-MichelBlakemore, Stephen J.Clawson, AliciaSuttle, BenjaminMcDonald, Alice A.Woodruff, MarkRibich, ScottHedrick, EricKeilhack, HeikeThomson, BlytheOwa, TakashiCopeland, Robert A.Ho, Peter T. C.Ribrag, Vincent
- [39] A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple MyelomaBLOOD, 2022, 140 : 10182 - 10184Sia, HanlonTan, Peter T.Richter, JoshuaHo, Phoebe JoyCochrane, TaraQuach, HangDhakal, BinodProscurshim, IgorJiang, TonyMancino, EmarynSalhi, YacineStefano, SammicheliGudi, GirishGarton, AndrewFeldman, Eric J.Spencer, Andrew
- [40] A phase Ia/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Chmielowski, BartoszEjadi, SamuelFunke, RoelStalligs-Schmitt, ToddDenker, MitchFrohlich, Mark WalterFranzusoff, Alexis J.Abedi, MehrdadCristea, Mihaela C.